secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2026-08-04T20:10:16+00:00
Accession:  0001193125-26-332809
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure Q2 2026 net loss $15.3M; cash $176.4M funds operations into 2029
-----------------------------------------------------------------------

- Net loss of $15.3M ($0.31 per share) vs $15.4M ($1.14 per share) in Q2 2025.
- Cash, cash equivalents and marketable securities of $176.4M as of June 30, 2026; runway into 2029.
- R&D expenses flat at $12.6M; G&A up $0.6M to $4.3M on higher personnel and consulting costs.
- IND submissions for PI3Kα pan-mutant candidates OKI-345 (breast cancer) and OKI-355 (vascular anomalies) planned for 1H 2027.
- Hosted KOL event on PI3Kα selectivity; participated as exhibitor/sponsor at ISSVA World Congress 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/0001193125-26-332809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/okur-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-332809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer